Thrombin is a therapeutic target for non-small-cell lung cancer to inhibit vasculogenic mimicry formation

吉非替尼 血管生成拟态 凝血酶 肺癌 水蛭素 癌症研究 血栓调节蛋白 转移 医学 癌症 免疫学 病理 表皮生长因子受体 内科学 血小板
作者
Bing Zhao,Meng‐Fang Wu,Zhihuang Hu,Yixin Ma,Wang Qi,Yanling Zhang,Yaran Li,Min Yu,Huijie Wang,Wei Mo
出处
期刊:Signal Transduction and Targeted Therapy [Springer Nature]
卷期号:5 (1) 被引量:45
标识
DOI:10.1038/s41392-020-0167-1
摘要

Abstract Tumor cells transform into endothelial cells by epithelial-to-mesenchymal transition, which is characterized by vasculogenic mimicry (VM). VM not only accelerates tumor progression but also increases drug-induced resistance. However, very little is currently known about the molecular determinants that enable VM. Targeting VM might bring a new breakthrough in cancer treatment. Thrombin is the key enzyme of the blood coagulation system and could contribute to tumor progression. Nevertheless, the association between thrombin and VM formation remains largely unknown. We found that VM was associated with the overall survival of non-small-cell lung cancer (NSCLC) patients, and that thrombin expression was closely related to VM formation. This research revealed that thrombin induced VM formation via PAR-1-mediated NF-κB signaling cascades. The novel thrombin inhibitors r-hirudin and DTIP inhibited VM formation and spontaneous metastases in subcutaneous tumors. Clinical pathological analysis confirmed that NSCLC patients with thrombin-positive/PAR-1-high expression had the poorest prognosis and were the most likely to form VM. The promotional activity of thrombin in VM formation and tumor metastasis was abolished in PAR-1-deficient NSCLC cells. The EGFR inhibitor gefitinib had no effect on VM and increased VEGF expression in tumors. The combination therapy of DTIP and gefitinib achieved a better therapeutic effect than either agent alone. This study is the first to illustrate that thrombin substantially contributes, together with PAR-1, to VM formation and to illustrate that VM might be a target of r-hirudin and DTIP to suppress tumor progression. The anticoagulants r-hirudin and DTIP could be employed for antitumor therapy. Combination therapy with DTIP with an EGFR inhibitor might achieve superior therapeutic effects.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
汉堡包应助YHF2采纳,获得10
刚刚
阿钟发布了新的文献求助10
1秒前
冯冯发布了新的文献求助10
1秒前
2秒前
2秒前
陈哥完成签到 ,获得积分10
3秒前
4秒前
生活的狗完成签到,获得积分10
6秒前
7秒前
EricFan完成签到,获得积分10
8秒前
深情不弱发布了新的文献求助10
8秒前
aa发布了新的文献求助10
9秒前
andrele应助哎健身采纳,获得10
9秒前
小二郎发布了新的文献求助10
11秒前
11秒前
11秒前
米线完成签到 ,获得积分10
14秒前
yunsww发布了新的文献求助10
17秒前
17秒前
18秒前
朴实的忆翠完成签到,获得积分10
19秒前
19秒前
CipherSage应助清秀的惜萱采纳,获得10
21秒前
czq发布了新的文献求助10
22秒前
gby2018发布了新的文献求助10
23秒前
24秒前
守拙给守拙的求助进行了留言
25秒前
鱼鳞飞飞发布了新的文献求助10
25秒前
26秒前
28秒前
年糕111发布了新的文献求助10
29秒前
29秒前
30秒前
32秒前
斯文败类应助虚心的问丝采纳,获得10
33秒前
su发布了新的文献求助10
34秒前
河马发布了新的文献求助10
35秒前
35秒前
orixero应助年糕111采纳,获得10
36秒前
羊羊得意完成签到,获得积分10
38秒前
高分求助中
The ACS Guide to Scholarly Communication 2500
Sustainability in Tides Chemistry 2000
Pharmacogenomics: Applications to Patient Care, Third Edition 1000
Studien zur Ideengeschichte der Gesetzgebung 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Threaded Harmony: A Sustainable Approach to Fashion 810
《粉体与多孔固体材料的吸附原理、方法及应用》(需要中文翻译版,化学工业出版社,陈建,周力,王奋英等译) 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3084785
求助须知:如何正确求助?哪些是违规求助? 2737877
关于积分的说明 7547149
捐赠科研通 2387454
什么是DOI,文献DOI怎么找? 1265984
科研通“疑难数据库(出版商)”最低求助积分说明 613207
版权声明 598429